RusnanoMedInvest
Venture capital company

RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.

About us

 

We are investing
in the development of innovative drugs

We are interested in cooperation with the authors of new promising ideas in the field of pharmaceuticals and medical equipment.

Portfolio

RMI - international cooperation

We implement an agreement between large and reputable companies in the United States and Russia

Rusnano and Domain have made an agreement on joint investments in pharmaceuticals and medical development for innovation.

About agreement

RusnanoMedInvest
Venture capital company

RMI is a subsidiary of RUSNANO JSC created in 2012 for the implementation of innovative projects in the field of medicine and pharmaceuticals.

Our history

RusnanoMedInvest (RMI) is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology

RMI was created in March 2012.

Initial funding - $380 million.

The RusnanoMedInvest fund was established by RUSNANO, the nanotechnology investment, research and development arm of the Russian Government together with Domain Associates LLC, one of the premier U.S. life sciences technology venture investment firms. The RusnanoMedInvest fund seeks, in addition to securing differentiated and sustainable returns to its investment portfolio, to promote the following social and developmental objectives in Russia

  • localization of innovative life sciences and pharmaceutical technology in Russia;
  • creation and accumulation of  Russian-originated world-class expertise in the field of venture capital financing in Life Sciences;
  • stimulating the interest of investors and potential investors in the financing of Russian life sciences ideas, concepts and technologies.

Read more

All Partners

All Portfolio

MEDIA CENTER

  • NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

    NovaMedica is starting construction of R&D Center for drug development using nanotechnologies

    NovaMedica, a Russian pharmaceutical company, is starting construction of R&D Center for innovative drug development and pilot production in Moscow. This Center will include laboratories and production areas equipped with state-of-the-art process equipment that has never been used in the Russian pharmaceutical industry before. The total investments are estimated approximately $15 million.

All news